Editas Medicine (EDIT)
(Delayed Data from NSDQ)
$3.19 USD
+0.23 (7.77%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.19 USD
+0.23 (7.77%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Zacks News
Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Editas (EDIT) delivered earnings and revenue surprises of -13.16% and 2.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Best Biotech Stocks & ETFs for mRNA, Gene Editing
by Neena Mishra
Here is what you should know about investing in these life changing technologies.
Editas (EDIT) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Editas' (EDIT) first-quarter earnings call, investor focus is expected to be on the company's progress with the development of its lead pipeline candidate - EDIT-101.
Vertex (VRTX) Ups Investment in CRISPR Gene Therapy Partnership
by Zacks Equity Research
Vertex (VRTX) to lead CRISPR Therapeutics for manufacture and commercialization of gene-editing therapy CTX001 which is being developed for treating SCD and TDT.
Why Is Editas (EDIT) Down 9.6% Since Last Earnings Report?
by Zacks Equity Research
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Software is the New Gold: Storing Value in the Digital-Crypto Age
by Kevin Cook
Time for the final nail in the gilded sarcophagus of the barbarous relic.
bluebird (BLUE) Up on Updated Findings in LentiGlobin's SCD Study
by Zacks Equity Research
bluebird (BLUE) gains following the updated findings from the reported case of AML in LentiGlobin for SCD gene therapy program.
Editas (EDIT) Misses on Q4 Earnings, Beats on Revenues
by Zacks Equity Research
Editas (EDIT) reports wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates. Pipeline development a key focus for the company.
Analysts Estimate Editas Medicine (EDIT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Editas (EDIT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Editas' (EDIT) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its CRISPR-based experimental candidate, EDIT-101.
Editas Medicine (EDIT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Editas Medicine (EDIT) closed the most recent trading day at $57.94, moving +1.35% from the previous trading session.
GameStop Lessons: Becoming a Savvy Investor with ETFs
by Kevin Cook
As more young investors take up day trading, I have a recipe for long-term wealth creation
Bear of the Day: CRISPR Therapeutics (CRSP)
by Kevin Cook
Gene editors got a big boost recently from sickle cell potential and Cathie Wood's thematic investing
5 Best ETFs for Young Investors
by Kevin Cook
As more young investors take up day trading, I have an important recipe for long-term wealth creation.
Editas Medicine (EDIT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Editas Medicine (EDIT) closed at $63.18, marking a +1.64% move from the previous day.
Editas Medicine (EDIT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Editas Medicine (EDIT) closed at $65.47, marking a -0.44% move from the previous day.
Bear of the Day: Illumina (ILMN)
by Kevin Cook
Maker of premier next-gen genomic sequencing technology lowers guidance but shares make new highs
CRISPR (CRSP) Up More Than 80% in Past 3 Months: Here's Why
by Zacks Equity Research
CRISPR Therapeutics' (CRSP) lead gene-editing candidate CTX001, being developed for treating SCD and TDT, holds potential. It has a strong partner in Vertex.
Editas (EDIT) Up More Than 100% in Past 3 Months: Here's Why
by Zacks Equity Research
Editas' (EDIT) lead candidate EDIT-101, that employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating SCD.
Editas Medicine (EDIT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Editas Medicine (EDIT) closed at $76.14 in the latest trading session, marking a +0.29% move from the prior day.
Editas (EDIT) Gets FDA Nod to Begin Safety Study on EDIT-301
by Zacks Equity Research
The FDA clears the initiation of the safety phase of Editas' (EDIT) early-stage study on investigational gene-editing therapy EDIT-301 for treating sickle cell disease. Shares down.
The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex Pharmaceuticals
CRISPR Gene Editing Stocks Up After Intellia's Pipeline Update
by Kinjel Shah
Shares of Intellia were up as the update on its gene-editing drugs excited investors. The news also pushed up stocks of companies making gene-editing drugs, FATE, CRSP, EDIT, using CRISPR technology.
Bull of the Day: Meridian Bioscience (VIVO)
by Kevin Cook
Small-cap diagnostics player will grow sales 20%+ to over $310 million on COVID-19 testing and its mutations
Cathie Put the Wood to Wall Street: TSLA, SQ, ROKU, CRSP, BIDU
by Kevin Cook
Her focus on disruptive innovation broke the mold of Wall Street money management.